Selective IgA2 deficiency in a patient with small intestinal Crohn’s disease
The Journal of clinical investigation(2022)
Abstract
The human IgA response is composed of two structurally different subclasses termed IgA1 and IgA2. Compared to IgA1, IgA2 has a shorter hinge region, which makes it more resistant to bacterial proteases. IgA1 is produced both systemically and in mucosal surfaces, whereas IgA2 is mostly confined to the intestines. While the overall IgA response is known to be involved in intestinal homeostasis, the specific contribution of IgA1 and IgA2 remains largely unknown ([Chen 2020][1]). Selective IgA deficiency (SIgAD) is the most prevalent primary immune deficiency. About half of SIgAD cases are associated with heterogeneous but generally mild clinical manifestations. Anecdotal evidence of IgA2 deficiency is available ([van Loghem 1983][2], [Ozawa 1986][3], [Engström 1990][4]), however no associations with clinical manifestations have been reported.
Here, we describe the occurrence of a selective IgA2 deficiency in a patient (CD068) with small intestinal Crohn’s disease (CD). The patient had undetectable IgA2+ cells and secreted IgA2 antibody in both intestine and circulation. Among other features, patient CD068 presented with duodenal and ileal inflammation. To our knowledge, this is the first case of IgA2 deficiency with a potential link to IBD, which might shed new insights into potential IgA2-specific functions.
### Competing Interest Statement
The authors have declared no competing interest.
### Funding Statement
This work was supported by the following grants: Anonymous Donor (SM and JFC), NIH/NIDDK R01 123749 (SM).
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the institutional review board of the Icahn School of Medicine at Mount Sinai (17-01304).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
All data produced in the present study are available upon reasonable request to the authors
[1]: #ref-1
[2]: #ref-2
[3]: #ref-3
[4]: #ref-4
MoreTranslated text
Key words
small intestinal crohns,iga<sub>2</sub>deficiency,disease
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined